Genentech Commits $750 Million to US Fill-Finish Plant as OncoSil Wins FDA Approval for Pancreatic Radiation Device

Genentech, the South San Francisco-based biotech subsidiary of Roche, on August 21 announced a $750 million investment in a new pharmaceutical fill-finish manufacturing facility in Holly Springs, North Carolina. The 700,000-square-foot plant will add sterile injectable manufacturing capacity for the company's biologics pipeline and is expected to create 700 jobs by 2029. The same day, Australia's OncoSil Medical secured FDA approval for its OncoSil catheter-based brachytherapy device targeting unresectable pancreatic cancer — the first new treatment approved for the indication in 12 years.

The Genentech Investment

The Holly Springs site will be Genentech's seventh US manufacturing facility and its first dedicated to sterile fill-finish for biologic products. The plant will handle vial filling, syringe filling and cartridge filling for compounds including the company's PD-L1 inhibitor atezolizumab (Tecentriq), the antibody-drug conjugate trastuzumab emtansine (Kadcyla), and several pipeline assets in Phase 3. Genentech CEO Aviv Reich said the investment is "a response to the chronic sterile-injectable capacity shortage that has constrained our ability to launch new biologics on schedule." The site is expected to come online in Q4 2028 and reach commercial output by Q2 2029.

Why Fill-Finish Capacity Matters

Sterile injectable fill-finish is the most capacity-constrained link in the biologics supply chain. The 2024 biolytic shortages of carboplatin and cisplatin — caused in part by a Pfizer plant shutdown and in part by chronic under-investment in fill-finish capacity — pushed the FDA to publish a sterile-injectable capacity map in March 2025. Since then, the agency has signaled that any new biologic approval with projected demand above 100,000 vials per year will be reviewed for capacity readiness before launch. Genentech's investment is one of seven major fill-finish commitments since 2024; Eli Lilly, Novartis and Bristol-Myers Squibb have made similar announcements.

OncoSil's Approval

OncoSil Medical, an Australian medtech listed on the ASX, on August 21 received FDA approval for its OncoSil catheter-based brachytherapy device, which delivers a single 30-minute injection of phosphorus-32 directly into unresectable pancreatic tumors. The approval covers patients with locally advanced pancreatic adenocarcinoma who have responded to or stabilized after initial chemotherapy, in combination with standard gemcitabine plus nab-paclitaxel. The device uses the same radioisotope as the legacy OncoSil system that had been approved in Europe and Singapore since 2023 but had failed to win FDA approval until the latest randomized PANFIRE III trial.

The PANFIRE III Trial Results

The PANFIRE III trial enrolled 174 patients across 14 US sites and randomized them to standard chemotherapy plus OncoSil versus standard chemotherapy alone. The OncoSil arm showed a median overall survival of 14.7 months versus 11.3 months for chemotherapy alone, a 30% improvement that the FDA accepted as the primary endpoint for accelerated approval. The device's most serious adverse event was post-procedural pancreatitis in 8% of patients, manageable with standard supportive care. OncoSil Medical said the device will be commercially available in the US within 60 days at a wholesale acquisition cost of $38,500 per procedure.

The Pancreatic Cancer Burden

Pancreatic cancer is the third-leading cause of cancer death in the US, with a five-year survival rate of 13% — the lowest of any major cancer. Approximately 64,000 Americans are diagnosed each year, and 80% of cases present as unresectable at diagnosis. The standard of care for locally advanced disease has been FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy, both of which extend survival by 3-5 months over no treatment. The OncoSil approval is the first device-based therapy to demonstrate a survival benefit over chemotherapy alone in this population.

What to Watch Through Year-End

Three checkpoints follow. The Q3 CMS rule on transitional pass-through payments for OncoSil, expected in November, will determine whether Medicare reimburses the device at a rate that supports hospital adoption or whether the $38,500 WAC creates a coverage delay. The PANFIRE III confirmatory trial readout, expected in Q1 2027, will provide the two-year overall survival data the FDA requires for full approval. And Genentech's broader manufacturing buildout — the company has signaled it may add a second fill-finish site in 2027 — will indicate whether the industry capacity correction is structural or whether the current wave of investment produces an oversupply by 2030.